One in four patients in latest clinical study show no symptoms of obstructive sleep apnea after vivos treatment

Highlands ranch, colo., july 13, 2021 (globe newswire) -- vivos therapeutics, inc . (the “company” or “vivos”) (nasdaq: vvos), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (osa), today announced results from a national study commissioned by the company to assess patients' airway function and osa symptoms after undergoing the vivos treatment.
VVOS Ratings Summary
VVOS Quant Ranking